Form 4: Akari Director Boosts Stake via Warrants and Note Exchange

Akari Therapeutics Director Raymond Prudo-Chlebosz acquired over 2 million derivative securities, including warrants and pre-funded warrants, through a private placement and a note exchange agreement.

Summary

• Raymond Prudo-Chlebosz, a Director of Akari Therapeutics Plc (AKTX), acquired 2,010,638 derivative securities on December 16, 2025.
• The acquisition included 618,658 unregistered pre-funded warrants (PIPE PFWs) and 618,658 accompanying Series G Warrants through a private placement, at a combined purchase price of $0.4041 per unit.
• An additional 386,661 unregistered pre-funded warrants (Note Exchange Unregistered Pre-Funded Warrants) and 386,661 unregistered warrants (Note Exchange Unregistered Warrants) were acquired through a note cancellation and exchange agreement.
• The note exchange involved the Director exchanging the entire outstanding principal and accrued interest on an unsecured promissory note held by the Director for these warrants.
• All acquired warrants and pre-funded warrants are exercisable upon shareholder approval.
• The Series G Warrants and Note Exchange Unregistered Warrants have an exercise price of $0.3883 per American Depositary Share (ADS) and a five-year term from shareholder approval.
• The PIPE PFWs and Note Exchange Unregistered Pre-Funded Warrants have an exercise price of $0.00001 per ADS and remain exercisable until fully exercised.
• Each ADS represents 2,000 Ordinary Shares of Akari Therapeutics Plc.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. A director increasing their stake, especially through a private placement and debt conversion, can be seen as a vote of confidence. However, the requirement for shareholder approval and potential dilution introduce some uncertainty.

Positives

• A Director increasing their beneficial ownership through the acquisition of warrants can signal confidence in the company's future prospects.
• The conversion of an unsecured promissory note into equity-linked securities reduces the company's debt burden and strengthens its balance sheet.

Negatives

• The exercisability of all acquired warrants and pre-funded warrants is contingent upon shareholder approval, introducing an element of uncertainty.
• The potential exercise of these warrants could lead to dilution for existing shareholders, increasing the total number of outstanding ADSs.

Risks

• Shareholder approval for the exercisability of the warrants and pre-funded warrants is not guaranteed, which could impact the value of these securities.
• Future market price volatility of Akari Therapeutics' ADSs could affect the value and attractiveness of exercising the warrants.
• Potential dilution from the future exercise of these warrants could negatively impact the per-share value for existing shareholders.

Future Outlook

The future outlook for these derivative securities is contingent on obtaining shareholder approval for their exercisability. Once approved, the Series G Warrants and Note Exchange Unregistered Warrants will have a five-year term, while the pre-funded warrants will remain exercisable until fully utilized.

Industry Context

Biotechnology and pharmaceutical companies often utilize private placements and debt-to-equity conversions as financing mechanisms, particularly for early-stage development or to manage debt. The acquisition of warrants by a director is a common insider transaction, reflecting a personal investment in the company's future performance.

Comparison to Industry Standards

• Private placements are a standard financing tool for biotech companies, allowing them to raise capital from a select group of investors without the extensive regulatory requirements of a public offering.
• Debt-to-equity conversions, such as the note cancellation and exchange, are also common in the industry to reduce leverage and improve balance sheet health, often involving existing creditors or insiders.
• The terms of the warrants, including exercise prices and expiration dates, are generally within the range seen in similar transactions for development-stage biotech firms, balancing investor upside with company financing needs.

Corporate Governance

Related Party Transactions

• The note cancellation and exchange agreement between Akari Therapeutics and Director Raymond Prudo-Chlebosz, where an unsecured promissory note held by the Director was exchanged for warrants and pre-funded warrants, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution if the warrants are exercised, requiring a vote for exercisability.
• Director (Raymond Prudo-Chlebosz): Increased beneficial ownership and potential for significant upside if the company's stock price increases.
• Creditors: The conversion of a promissory note held by the director reduces the company's debt obligations to that specific party.

Next Steps

• Akari Therapeutics will need to seek shareholder approval for the exercisability of the acquired warrants and pre-funded warrants.

Key Dates

Keywords

Akari Therapeutics, AKTX, Form 4, Insider Transaction, Director, Warrants, Pre-Funded Warrants, Private Placement, Note Exchange, Beneficial Ownership, SEC Filing, Derivative Securities, Shareholder Approval, Dilution